NeuroPharm, a subsidiary of Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF), has partnered with FreeMind Group to explore global non-dilutive funding for its innovative mental wellness products targeting high-risk populations like veterans. This partnership aims to leverage FreeMind's expertise in securing funding, crucial for advancing NeuroPharm's psilocybin-based therapies for PTSD, depression, and other mental health issues. Additionally, the Company has settled $847,500 in debt through the issuance of common shares.
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) announced that its subsidiary, NeuroPharm Inc., has filed a provisional patent application with the USPTO for a psychedelic therapy enhancer aimed at treating psychiatric disorders like PTSD. The patent covers an enhancer that reduces the breakdown of psilocin, potentially leading to improved therapeutic effects with lower doses. This aligns with NeuroPharm's mission to develop psilocybin-based treatments for mental health issues in veterans and first responders, leveraging evidence-based medicine.
Mydecine Innovations Group has launched its digital telehealth mobile application, Mindleap Health, aimed at enhancing access to mental health services and analytics. The platform allows users to connect with approved mental health specialists and utilizes a unique revenue model, charging a 9% fee on services purchased. The telehealth market is projected to reach $560 billion by 2027, representing a 25.2% compound annual growth rate. Founder Nikolai Vassev emphasized the innovative technology and continuous improvement focus in developing advanced mental health analytics.